Blackpool CCG medicines optimisation

Blackpool CCG medicines optimisation

Medicines play an important part in promoting well-being, preventing ill health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines management can be defined in several ways:

  • The clinical, cost-effective, safe and secure handling of medicines
  • A system of processes and behaviours that determines how medicines are used by the NHS and patients
  • Enabling people to make the best possible use of medicines
  • Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s medicines management team on 01253 951306 or email


Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

28 Day Prescribing 0.3 MB215
Camouflaging Products 0.2 MB57
Cannabis based medicinal products for pain POSITION STATEMENT 0.3 MB187
Clinical Need Low Priority Medicines - General 0.3 MB331
Clinical Need Soluble Analgesics 0.5 MB359
Clinical Need Thickeners Position Statement 0.3 MB221
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB158
Denosumab Position Statement 0.3 MB148
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB191
Edoxaban Position Statement 0.2 MB170
Emollients and Sunscreens 0.2 MB276
Free of Charge (FOC) Medicines schemes 0.3 MB160
Generic Biosimilar Medicines Position Statement 0.2 MB159
Generic Prescribing Guidelines 0.3 MB268
Glucose Monitoring Devices 0.5 MB222
Gluten Free Foodstuffs 0.2 MB174
Health Professionals e-cigarettes briefing 0.2 MB139
Holiday Medication 0.2 MB241
Liothyronine 0.2 MB152
Ophthalmology Macular Pathways 1.1 MB158
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB230
Out of Area Prescribing 0.2 MB121
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB190
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB47
Position Statement Sip Feeds 0.4 MB181
Prescribing Nutritional Supplements Post Bariatric Surgery 0.3 MB161
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB142
Prescribing Vitamins And Minerals 0.3 MB144
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB129
Stoma Care Products - deodorants and air fresheners 0.4 MB190
Trans Anal Irrigation Devices 0.2 MB146
Vitamin D Position Statement 0.2 MB93
Zero Risk Schemes 0.3 MB138

Prescribing guidance

Asthma treatment guideline for children version 0.4 MB48
Axial-Spondyloarthritis-pathway-Version 37 KB109
Blood glucose meters and test strips Type 2 Diabetes V2.3 0.5 MB438
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB157
Chronic Non-cancer Pain Guidelines 0.7 MB139
Colomycin prescribing information sheet Non CF indications. 0.2 MB117
Constipation-Pathway-Version 0.7 MB333
COPD guideline 0.6 MB207
dementia medicines information sheet 0.3 MB40
Diabetes - Glucagon Like Peptide Contract 0.2 MB175
Diabetes - Home Monitoring of Blood Glucose Levels Guideline 0.2 MB288
DIABETES Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[1] 0.5 MB168
Diabetes-self-management-contract 0.5 MB210
Edoxaban Prescribing Tip 68 KB209
Erectile-Dysfunction-Guideline-Version 1.0 MB182
Flash Glucose Monitoring policy - L&SC 0.2 MB135
Gastroenterology-Biologics-Pathway-Version 0.4 MB183
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB145
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB284
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB98
Headache Management Guideline for Adults 0.7 MB115
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB138
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB129
Interim Gender Dysphoria protocol 0.6 MB131
Lancashire and South Cumbria Self-Care and Acces to OTC Medicines – Temp... 83 KB46
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB601
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB46
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB168
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB279
Neuropathic Pain Guidance (Version 1.2) 0.9 MB179
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB159
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB137
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB189
Primary Care Good Prescribing Guide 0.6 MB351
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB148
Psoriasis LMMG Biologic and High Cost Drug Commissioning Pathway v-1.6[1] 0.4 MB210
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB198
RA-High-Cost-Drugs-Pathway-v 0.2 MB164
Restless Legs Syndrome guidelines 0.3 MB110
Rheumatoid Arthritis Pathway Guideline 0.1 MB54
SIP Feeds 0.1 MB200
Trans male prescribing information sheet 0.2 MB75
Trans-female-gender-dysphoria-prescribing-information-sheet-version-1.1[1] 0.2 MB51
Wound care formulary 8.2 MB287

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document:

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started October 2018
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin)  – Started September 2018
  • Lixiana (Edoxaban) – Started October 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started June 2019
  • Seretide (Fluticasone / Salmeterol) – Started January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started October 2018
  • Xarelto (Rivaroxaban) – Started July 2019
  • Zoladex (Goserelin) – Started January 2019

Last updated on 18 December 2019 at 11:11 by Senior communications and engagement officer N